Sunday, September 27, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

View original at finance.yahoo.com
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Austedo annual revenues expected to be more than $2.5 billion by 2027

    80% confidence

  • Teva raised its 2025 Austedo sales expectations following IRA pricing negotiations conclusion

    80% confidence

  • The outcome of the IRA pricing negotiations for Austedo went as expected

    80% confidence

  • Teva expects five additional biosimilar launches by 2027

    80% confidence

  • Teva expects Uzedy total sales to be between $190 million and $200 million in 2025

    80% confidence

  • Teva aims to double its global biosimilars sales by 2027

    80% confidence

  • CMS is expected to formally announce the agreement on a maximum fair price for Austedo in November 2025

    80% confidence

  • Austedo sales expected to exceed $3 billion by 2030

    80% confidence

  • Teva anticipates generating more than $5 billion in revenues from its branded products by 2030

    80% confidence

  • In 2025, Teva expects its generics business to be flat to up in low single digits in constant currency terms

    80% confidence

  • Teva is a Hold stock with Zacks Rank #3

    80% confidence

  • Teva expects an adjusted operating margin of 30% by 2027 through cost savings and continued growth of branded drugs

    80% confidence

  • Teva expects to launch Austedo in European markets in 2026

    80% confidence

  • Teva expects to file a new drug application for olanzapine before the year ends

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play — Source | Via News | Via News